Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Thymoglobulin and Low Dose Cyclosporine for GVHD Prophylaxis
NCT03456817Phase 2Terminated
- Sponsor
- American Health Staffing Group
- Start
- Jul 2020
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of antithymocyte globulin rabbit in graft-versus-host disease (GVHD), sponsored by American Health Staffing Group. Started Jul 2020; status: terminated.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03456817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03456817.